Publicaciones (19) Publicaciones en las que ha participado algún/a investigador/a

2012

  1. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment

    Oncotarget, Vol. 3, Núm. 12, pp. 1600-1614

  2. Bortezomib action in multiple myeloma: MicroRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?

    Blood Cancer Journal

  3. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: A randomized phase II trial

    Annals of Oncology, Vol. 23, Núm. 7, pp. 1780-1788

  4. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: A randomised phase II study

    British Journal of Cancer, Vol. 107, Núm. 3, pp. 435-441

  5. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

    Breast Cancer Research and Treatment, Vol. 134, Núm. 3, pp. 1161-1168

  6. Encuesta nacional sobre la actitud ante el hallazgo de metástasis en el ganglio centinela por cáncer de mama en distintas unidades hospitalarias

    Revista de Senologia y Patologia Mamaria, Vol. 25, Núm. 3, pp. 89-95

  7. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

  8. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

    Cancer, Vol. 118, Núm. 1, pp. 241-247

  9. First-line bevacizumab-containing therapy for breast cancer: Results in patients aged ≥70 years treated in the ATHENA study

    Annals of Oncology, Vol. 23, Núm. 1, pp. 111-118

  10. Funciones y organización de un comité de neurooncologí a en un hospital con servicio de neurocirugía

    Neurocirugia, Vol. 23, Núm. 4, pp. 151-156

  11. Haemoperitoneum as an indicator of GIST

    Anti-Cancer Drugs, Vol. 23, Núm. SUPPL. 1

  12. Identification of a biomarker panel for colorectal cancer diagnosis

    BMC Cancer, Vol. 12

  13. Maintenance treatment in non-small-cell lung cancer: A new treatment paradigm?

    Cancer and Chemotherapy Reviews, Vol. 7, Núm. 3, pp. 147-154

  14. Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells

    Molecular Cancer, Vol. 11

  15. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers

    BMC Medical Genomics, Vol. 5

  16. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis

    Cancer Research, Vol. 72, Núm. 11, pp. 2879-2888

  17. SEOM guidelines for cervical cancer

    Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 516-519

  18. SEOM guidelines for endometrial cancer

    Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 512-515

  19. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: A double-blind, placebo-controlled, randomized Phase II study

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 681-687